CN105612167A - 替诺福韦二吡呋酯磷酸二氢盐 - Google Patents

替诺福韦二吡呋酯磷酸二氢盐 Download PDF

Info

Publication number
CN105612167A
CN105612167A CN201480055828.5A CN201480055828A CN105612167A CN 105612167 A CN105612167 A CN 105612167A CN 201480055828 A CN201480055828 A CN 201480055828A CN 105612167 A CN105612167 A CN 105612167A
Authority
CN
China
Prior art keywords
tenofovir
tenofovir disoproxil
pyrrole furan
furan ester
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480055828.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍兰
L·里德万
M·萨帕德洛
O·达马
J·贝拉尼克
V·克拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of CN105612167A publication Critical patent/CN105612167A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201480055828.5A 2013-10-09 2014-09-22 替诺福韦二吡呋酯磷酸二氢盐 Pending CN105612167A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13004844.0A EP2860184B1 (en) 2013-10-09 2013-10-09 Dihydrogenphosphate salt of Tenofovir disoproxil
EP13004844.0 2013-10-09
PCT/EP2014/002562 WO2015051875A1 (en) 2013-10-09 2014-09-22 Dihydrogenphosphate salt of tenofovir disoproxil

Publications (1)

Publication Number Publication Date
CN105612167A true CN105612167A (zh) 2016-05-25

Family

ID=49354420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480055828.5A Pending CN105612167A (zh) 2013-10-09 2014-09-22 替诺福韦二吡呋酯磷酸二氢盐

Country Status (10)

Country Link
EP (1) EP2860184B1 (enExample)
JP (1) JP2016534047A (enExample)
KR (1) KR20160067843A (enExample)
CN (1) CN105612167A (enExample)
BR (1) BR112016007617A2 (enExample)
EA (1) EA201690622A1 (enExample)
IL (1) IL244848A0 (enExample)
MX (1) MX2016003757A (enExample)
PT (1) PT2860184T (enExample)
WO (1) WO2015051875A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160003532A (ko) * 2014-07-01 2016-01-11 한미약품 주식회사 테노포비어 디소프록실 인산염과, 비금속염 붕해제 및 비금속염 활택제를 포함하는 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007392A2 (en) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
CN101918418A (zh) * 2007-12-12 2010-12-15 阿尔迪默菲克斯技术有限责任公司 替诺福韦地索普西的固体形式
US20110112292A1 (en) * 2008-04-25 2011-05-12 Cipla Limited Crystalline Form of Tenofovir Disoproxil and a Process for Its Preparation
CN101781334B (zh) * 2010-03-04 2012-11-28 福建广生堂药业股份有限公司 替诺福韦酯的盐化合物，其制备方法和药物应用
WO2013132314A1 (en) * 2012-03-05 2013-09-12 Laurus Labs Private Limited Tenofovir phosphate, processes for the preparation and pharmaceutical composition thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
PT915894E (pt) 1996-07-26 2003-10-31 Gilead Sciences Inc Analogos de nucleotidos
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
ATE305009T1 (de) 1997-07-25 2005-10-15 Gilead Sciences Inc Nukleotid-analog zusamensetzung und synthese verfahren
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
WO2008140302A1 (en) 2007-05-14 2008-11-20 Ultimorphix Technologies B.V. Polymorphic forms of tenofovir disoproxil fumarate
WO2008143500A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009064174A1 (en) 2007-11-14 2009-05-22 Ultimorphix Technologies B.V. Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
CN103282369A (zh) * 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007392A2 (en) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
CN101918418A (zh) * 2007-12-12 2010-12-15 阿尔迪默菲克斯技术有限责任公司 替诺福韦地索普西的固体形式
US20110112292A1 (en) * 2008-04-25 2011-05-12 Cipla Limited Crystalline Form of Tenofovir Disoproxil and a Process for Its Preparation
CN101781334B (zh) * 2010-03-04 2012-11-28 福建广生堂药业股份有限公司 替诺福韦酯的盐化合物，其制备方法和药物应用
WO2013132314A1 (en) * 2012-03-05 2013-09-12 Laurus Labs Private Limited Tenofovir phosphate, processes for the preparation and pharmaceutical composition thereof

Also Published As

Publication number Publication date
MX2016003757A (es) 2016-07-08
EP2860184B1 (en) 2018-08-29
JP2016534047A (ja) 2016-11-04
KR20160067843A (ko) 2016-06-14
IL244848A0 (en) 2016-05-31
PT2860184T (pt) 2018-11-20
WO2015051875A1 (en) 2015-04-16
EP2860184A1 (en) 2015-04-15
EA201690622A1 (ru) 2016-08-31
BR112016007617A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
CN101891738B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
RU2704795C2 (ru) Кристаллическая форма бисульфата ингибитора jak и способ ее получения
CN107531682A (zh) B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
WO2017174044A1 (en) Solid forms of ibrutinib
KR102878525B1 (ko) 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법
CZ2016391A3 (cs) Farmaceutická formulace olaparibu
CN105601635A (zh) 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
WO2018073574A1 (en) Polymorphic forms of palbociclib
WO2016151304A1 (en) Novel polymorphic form x of nilotinib dihydrochloride hydrate
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
CZ201769A3 (cs) Pevné formy venetoclaxu
JP2016534047A (ja) テノホビルジソプロキシルの二水素リン酸塩
EP3004102A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2014193881A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2015035817A1 (zh) 一种肌醇晶体及其制备方法和用途
US20190248773A1 (en) Process for the preparation of pure and stable crystalline raltegravir potassium form 3
CN121194965A (zh) 盐酸奥扎莫德的无定形形式和晶型
WO2017029408A1 (en) Solid state forms of sofosbuvir
WO2016127962A1 (en) An amorphous solid form of suvorexant with sulphuric acid
CN106432224A (zh) 一种氘代Palbociclib羟乙基磺酸盐的结晶
JP2016534047A5 (enExample)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160525